# Adagene Inc.: overview ADAG · Nasdaq · CIK 1818838 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/adag.md) · [Financials](/companies/adag/financials.md) · [Filings](/companies/adag/filings.md) · [Insiders](/companies/adag/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.2](/filings/0001104659-24-041109.md) | [9.3](/filings/0001410578-25-000419.md) | [18.1](/filings/0001104659-26-038612.md) | [0.1](/filings/0001104659-26-038612.md) | [7.7](/filings/0001104659-26-038612.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(711.2%)](/filings/0001104659-24-041109.md) | [(903.1%)](/filings/0001410578-25-000419.md) | [(131.0%)](/filings/0001104659-26-038612.md) | [(34835.4%)](/filings/0001104659-26-038612.md) | [(279.5%)](/filings/0001104659-26-038612.md) | | Net margin | % | [(719.2%)](/filings/0001104659-24-041109.md) | [(860.6%)](/filings/0001410578-25-000419.md) | [(104.6%)](/filings/0001104659-26-038612.md) | [(32386.4%)](/filings/0001104659-26-038612.md) | [(229.6%)](/filings/0001104659-26-038612.md) | | Diluted EPS | $ per share | [(1.46)](/filings/0001104659-24-041109.md) | [(1.48)](/filings/0001410578-25-000419.md) | [(0.35)](/filings/0001104659-26-038612.md) | [(0.59)](/filings/0001104659-26-038612.md) | [(0.30)](/filings/0001104659-26-038612.md) | | Free cash flow | $m | [(45.9)](/filings/0001104659-24-041109.md) | [(49.3)](/filings/0001410578-25-000419.md) | [(28.5)](/filings/0001104659-26-038612.md) | [(29.7)](/filings/0001104659-26-038612.md) | [(15.7)](/filings/0001104659-26-038612.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/adag/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $28.1m | 6,666,666 | | Not compared | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $11.2m | 2,666,666 | | New +2,666,666 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $11.2m | 2,666,666 | | New +2,666,666 | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $7.2m | 1,716,711 | | Added +1,108,808 | | [HSG Holding Ltd](/funds/1470766.md) | 2026-06-30 | $5.6m | 1,343,364 | | Unchanged | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $5.3m | 1,250,000 | | New +1,250,000 | | [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $2.3m | 537,230 | | Added +502,455 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $2.1m | 506,934 | | New +506,934 | | [Exome Asset Management LLC](/funds/2011932.md) | 2026-06-30 | $2.1m | 488,293 | | Reduced −248,552 | | [Birchview Capital, LP](/funds/1618205.md) | 2026-06-30 | $1.0m | 240,000 | | New +240,000 | ## Recent filings [All 191 filings](/companies/adag/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-25 | 20:15 ET | [6-K](/filings/0001104659-26-110982.md) | Report of a foreign private issuer, period 2026-09-25 | 0001104659-26-110982 | | 2026-09-22 | 12:00 ET | [6-K](/filings/0001104659-26-109485.md) | Report of a foreign private issuer, period 2026-09-22 | 0001104659-26-109485 | | 2026-09-10 | 12:00 ET | [6-K](/filings/0001104659-26-106554.md) | Report of a foreign private issuer, period 2026-09-10 | 0001104659-26-106554 | | 2026-09-09 | 12:00 ET | [6-K](/filings/0001104659-26-106137.md) | Report of a foreign private issuer, period 2026-09-09 | 0001104659-26-106137 | | 2026-08-12 | 11:30 ET | [6-K](/filings/0001104659-26-094468.md) | Report of a foreign private issuer, period 2026-06-30 | 0001104659-26-094468 | | 2026-07-06 | 12:00 ET | [6-K](/filings/0001104659-26-080580.md) | Report of a foreign private issuer, period 2026-07-06 | 0001104659-26-080580 | | 2026-06-08 | 10:23 ET | [SCHEDULE 13D/A](/filings/0001104659-26-071145.md) | Ownership report, active investor, amended | 0001104659-26-071145 | | 2026-04-17 | 20:00 ET | [6-K](/filings/0001104659-26-044885.md) | Report of a foreign private issuer, period 2026-04-17 | 0001104659-26-044885 | | 2026-04-02 | 11:11 ET | [6-K](/filings/0001104659-26-038868.md) | Report of a foreign private issuer, period 2026-04-02 | 0001104659-26-038868 | | 2026-04-02 | 10:59 ET | [6-K](/filings/0001104659-26-038858.md) | Report of a foreign private issuer, period 2026-04-02 | 0001104659-26-038858 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-038612.md), filed Apr 1, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1818838 - Tickers: ADAG - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: E9 - Filer category: Accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.